Thalidomide, a drug reviled in the 1960s for its teratogenic effects, has been revived in recent years for cancer and leprosy therapy. A study now finds another use for this drug in vascular disease, providing further insights into the drug's mechanisms of action (pages 420–428).
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Vargesson, N. Bioessays 31, 1327–1336 (2009).
D'Amato, R.J., Loughnan, M.S., Flynn, E. & Folkman, J. Proc. Natl. Acad. Sci. USA 91, 4082–4085 (1994).
Deeken, J.F. et al. Pharmacogenomics J. advance online publication, doi:10.1038/tpj.2009.57 (29 December 2009).
Lebrin, F. et al. Nat. Med. 16, 420–428 (2010).
Flieger, D., Hainke, S. & Fischbach, W. Ann. Hematol. 85, 631–632 (2006).
Mitchell, A. et al. Liver Transpl. 14, 210–213 (2008).
Daniel, T.O., Gibbs, V.C., Milfay, D.F. & Williams, L.T. J. Biol. Chem. 262, 11893–11896 (1987).
Hirschi, K.K., Burt, J.M., Hirschi, K.D. & Dai, C. Circ. Res. 93, 429–437 (2003).
Li, X. et al. Anticancer Res. 23, 2481–2487 (2003).
Rogers, M.S., Rohan, R.M., Birsner, A.E. & D'Amato, R.J. FASEB J. 17, 2112–2114 (2003).
Tang, Y. et al. Hum. Mol. Genet. 12, 1579–1589 (2003).
Bourdeau, A. et al. Am. J. Pathol. 158, 2011–2020 (2001).
Rohan, R.M., Fernandez, A., Udagawa, T., Yuan, J. & D'Amato, R.J. FASEB J. 14, 871–876 (2000).
The author declares no competing financial interests.
About this article
Cite this article
Akhurst, R. Taking thalidomide out of rehab. Nat Med 16, 370–372 (2010). https://doi.org/10.1038/nm0410-370